Review of blood pressure control rates and outcomes

Journal of the American Society of Hypertension

Volumn 8, Issue 2, 2014, Pages 127-141

  Bakris, George ^a   Sarafidis, Pantelis ^a   Agarwal, Rajiv ^b   Ruilope, Luis ^c  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

cardiovascular diseases; drug therapy; Hypertension; morbidity; mortality

Indexed keywords

CARDIOVASCULAR DISEASES; DRUG THERAPY; HYPERTENSION; MORBIDITY; MORTALITY;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MEDICATION THERAPY MANAGEMENT; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84894030074     PISSN: 19331711     EISSN: 18787436     Source Type: Journal    
DOI: 10.1016/j.jash.2013.07.009     Document Type: Review

References (52)

1. A.S. Go, D. Mozaffarian, V.L. Roger, E.J. Benjamin, J.D. Berry, and W.B. Borden et al. Heart disease and stroke statistics - 2013 update - a report from the American Heart Association Circulation 127 2013 143 152
2. P.A. Heidenreich, J.G. Trogdon, O.A. Khavjou, J. Butler, K. Dracup, and M.D. Ezekowitz et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association Circulation 123 2011 933 944
3. G. Mancia, S. Laurent, E. Agabiti-Rosei, E. Ambrosioni, M. Burnier, and M.J. Caulfield et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document Blood Press 18 2009 308 347
4. A.H. Gradman, J.N. Basile, B.L. Carter, and G.L. Bakris Combination therapy in hypertension J Am Soc Hypertens 4 2010 42 50
5. A.H. Gradman Strategies for combination therapy in hypertension Curr Opin Nephrol Hypertens 21 2012 486 491
6. S.D. Persell Prevalence of resistant hypertension in the United States, 2003-2008 Hypertension 57 2011 1076 1080
7. D.S. Echt, P.R. Liebson, L.B. Mitchell, R.W. Peters, D. Obias-Manno, and A.H. Barker et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial N Engl J Med 324 1991 781 788
8. J.C. Tardif, T. Heinonen, D. Orloff, and P. Libby Vascular biomarkers and surrogates in cardiovascular disease Circulation 113 2006 2936 2942
9. F. Turnbull Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 2003 1527 1535
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
11. M.R. Law, J.K. Morris, and N.J. Wald Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 338 2009 b1665
12. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) JAMA 265 1991 3255 3264
13. B. Dahlof, L.H. Lindholm, L. Hansson, B. Schersten, T. Ekbom, and P.O. Wester Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet 338 1991 1281 1285
14. MRC Working Party Medical Research Council trial of treatment of hypertension in older adults: principal results BMJ 304 1992 405 412
15. J.D. Neaton, R.H. Grimm Jr., R.J. Prineas, J. Stamler, G.A. Grandits, and P.J. Elmer et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group JAMA 270 1993 713 724
16. J.A. Staessen, R. Fagard, L. Thijs, H. Celis, G.G. Arabidze, and W.H. Birkenhager et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Lancet 350 1997 757 764
17. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
18. T. Berl, L.G. Hunsicker, J.B. Lewis, M.A. Pfeffer, J.G. Porush, and J.L. Rouleau et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy Ann Intern Med 138 2003 542 549
19. L. Hansson, L.H. Lindholm, L. Niskanen, J. Lanke, T. Hedner, and A. Niklason et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lancet 353 1999 611 616
20. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group Hypertension 34 1999 1129 1133
21. M.J. Brown, C.R. Palmer, A. Castaigne, P.W. de Leeuw, G. Mancia, and T. Rosenthal et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) Lancet 356 2000 366 372
22. L. Hansson, T. Hedner, P. Lund-Johansen, S.E. Kjeldsen, L.H. Lindholm, and J.O. Syvertsen et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study Lancet 356 2000 359 365
23. B. Dahlof, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, and U. de Faire et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
24. L.M. Wing, C.M. Reid, P. Ryan, L.J. Beilin, M.A. Brown, and G.L. Jennings et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly N Engl J Med 348 2003 583 592
25. H. Lithell, L. Hansson, I. Skoog, D. Elmfeldt, A. Hofman, and B. Olofsson et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial J Hypertens 21 2003 875 886
26. C.J. Pepine, E.M. Handberg, R.M. Cooper-DeHoff, R.G. Marks, P. Kowey, and F.H. Messerli et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial JAMA 290 2003 2805 2816
27. S. Wassertheil-Smoller, B. Psaty, P. Greenland, A. Oberman, T. Kotchen, and C. Mouton et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women JAMA 292 2004 2849 2859
28. S. Julius, S.E. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, and L. Hansson et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031
29. B. Dahlof, P.S. Sever, N.R. Poulter, H. Wedel, D.G. Beevers, and M. Caulfield et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 366 2005 895 906
30. H. Suzuki, and Y. Kanno Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients Hypertens Res 28 2005 307 314
31. K. Jamerson, M.A. Weber, G.L. Bakris, B. Dahlof, B. Pitt, and V. Shi et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2008 2417 2428
32. JATOS Study Group Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS) Hypertens Res 31 2008 2115 2127
33. T. Ogihara, K. Nakao, T. Fukui, K. Fukiyama, K. Ueshima, and K. Oba et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial Hypertension 51 2008 393 398
34. H. Kasanuki, N. Hagiwara, S. Hosoda, T. Sumiyoshi, T. Honda, and K. Haze et al. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE) Eur Heart J 30 2009 1203 1212
35. T. Sawada, H. Yamada, B. Dahlof, and H. Matsubara Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study Eur Heart J 30 2009 2461 2469
36. M. Matsuzaki, T. Ogihara, S. Umemoto, H. Rakugi, H. Matsuoka, and K. Shimada et al. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial J Hypertens 29 2011 1649 1659
37. T. Muramatsu, K. Matsushita, K. Yamashita, T. Kondo, K. Maeda, and S. Shintani et al. Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study Hypertension 59 2012 580 586
38. H. Ogawa, S. Kim-Mitsuyama, K. Matsui, T. Jinnouchi, H. Jinnouchi, and K. Arakawa Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients Am J Med 125 2012 981 990
39. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) Arch Intern Med 153 1993 154 183
40. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Available at: http://www.nhlbi.nih.gov/guidelines/archives/jnc6/. Accessed May 6, 2013.
41. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo Jr. et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
42. G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, and G. Germano et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension J Hypertens 25 2007 1751 1762
43. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 21 2003 1011 1053
44. G. Mancia, S. Laurent, E. Agabiti-Rosei, E. Ambrosioni, M. Burnier, and M.J. Caulfield et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document J Hypertens 27 2009 2121 2158
45. 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting Bull World Health Organ 71 1993 503 517
46. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee J Hypertens 17 1999 151 183
47. J.A. Whitworth 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension J Hypertens 21 2003 1983 1992
48. W.C. Cushman, C.E. Ford, J.A. Cutler, K.L. Margolis, B.R. Davis, and R.H. Grimm et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) J Clin Hypertens (Greenwich) 4 2002 393 404
49. G.L. Bakris, M. Williams, L. Dworkin, W.J. Elliott, M. Epstein, and R. Toto et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Am J Kidney Dis 36 2000 646 661
50. K. Jamerson, G.L. Bakris, B. Dahlof, B. Pitt, E. Velazquez, and J. Gupte et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial Blood Press 16 2007 80 86
51. Guidance for industry. Hypertension indication: drug labeling for cardiovascular outcome claims. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm075072.pdf. Accessed May 6, 2013.
52. P. Kizilirmak, Y. Uresin, and O.B. Yildiz The efficacy and safety of triple vs dual combination of angiotensin ii receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis J Clin Hypertens (Greenwich) 15 2013 193 200